Microbiota: a key orchestrator of cancer therapy

Journal name:
Nature Reviews Cancer
Volume:
17,
Pages:
271–285
Year published:
DOI:
doi:10.1038/nrc.2017.13
Published online
Corrected online

Abstract

The microbiota is composed of commensal bacteria and other microorganisms that live on the epithelial barriers of the host. The commensal microbiota is important for the health and survival of the organism. Microbiota influences physiological functions from the maintenance of barrier homeostasis locally to the regulation of metabolism, haematopoiesis, inflammation, immunity and other functions systemically. The microbiota is also involved in the initiation, progression and dissemination of cancer both at epithelial barriers and in sterile tissues. Recently, it has become evident that microbiota, and particularly the gut microbiota, modulates the response to cancer therapy and susceptibility to toxic side effects. In this Review, we discuss the evidence for the ability of the microbiota to modulate chemotherapy, radiotherapy and immunotherapy with a focus on the microbial species involved, their mechanism of action and the possibility of targeting the microbiota to improve anticancer efficacy while preventing toxicity.

At a glance

Figures

  1. Local and systemic effects of the gastrointestinal microbiota.
    Figure 1: Local and systemic effects of the gastrointestinal microbiota.

    The abundant microbiota present on the gastrointestinal mucosa affects local mucosal homeostasis, functions and immunity7, 8, 9. Many of the mechanisms by which various bacterial species and their products and metabolites affect mucosal physiology and pathology have been described7, 8, 9, 10. However, the presence and composition of the gut microbiota also systemically affects the functions of most physiological systems, the pathology and the response to therapy in distant organs10. Some of the demonstrated or proposed mechanisms by which the gastrointestinal microbiota can achieve this are listed in the box at the top of the figure205. The microbiota and specific microbial species also affect neoplastic pathology both at the local level in the gastrointestinal tract145, 188, 206, 207 and systemically in organs that are not normally associated with the gut microbiota192, 193, 194, 208, 209, 210, 211, 212. Although these mechanisms have been studied primarily for the most abundant intestinal microbiota organisms, microorganisms colonizing other epithelial barriers, for example, the mouth and the skin, are also expected to mediate both local and systemic effects195, 195. In addition to its association with cancer development, the microbiota also has both a local and a systemic role in modulating the efficacy and toxicity of cancer therapy3. CNS, central nervous system; MALT, mucosa-associated lymphoid tissue.

  2. Major pathways of drug metabolism and the role of microbiota following enteral (for example, oral) or parenteral (for example, intravenous) administration.
    Figure 2: Major pathways of drug metabolism and the role of microbiota following enteral (for example, oral) or parenteral (for example, intravenous) administration.

    a | Enteral drug metabolism. Orally administered drugs (E1) sit in the stomach for 30–45 minutes before reaching the intestine and being absorbed into the liver by the portal circulation (E2). In the intestine, host and microbial enzymes induce metabolic alterations to the drug that together with direct binding to bacterial products and segregation control intestinal absorption43. In the liver, following phase I and phase II processing (first pass metabolism; E3), approximately 90% of the oral drug is metabolized and destroyed or eliminated through biliary secretion (E4). The drugs secreted into the intestine via the biliary duct can be reabsorbed via the portal circulation or excreted in stools. As a consequence, only 10% of the oral drug enters the circulation through the hepatic veins and is available to reach the target tumours and other tissues (E5). Phase I and phase II processing are also affected by the gut microbiota through the regulation of the level of host enzymes involved in drug processing. b | Parenteral drug metabolism. Following intravenous administration (P1) close to 100% of the drug enters the circulation and is available to reach the target tumours (P2); however, the drug is also distributed systemically, inducing adverse toxic reactions (P3). Any remaining drug not retained in tissues can be rapidly excreted by the kidney. Each minute 29% of the circulating drug is transported via the splanchnic circulation (hepatic, mesenteric and splenic arteries) to the liver (P4), where the drug is processed similarly to enterally administered drugs. The detoxified drugs that are secreted from the liver to the intestine through the biliary excretion route can be reactivated by bacterial enzymes, inducing intestinal toxicity. CYP450, cytochrome P450; GI, gastrointestinal.

  3. The gut microbiota regulates anticancer therapies.
    Figure 3: The gut microbiota regulates anticancer therapies.

    In physiological conditions, the commensals in the intestinal lumen are prevented from translocating through the intestinal mucosa by an intact epithelial barrier covered by a mucus layer that is poorly permeable to microorganisms. Treatment with platinum (Pt) drugs, total body irradiation (TBI), cyclophosphamide (CTX) and anti-cytotoxic T lymphocyte- associated antigen 4 (CTLA4) all cause damage to the mucus layer, which disrupts barrier integrity and enables bacteria to penetrate the lamina propria, which lies beneath the epithelium. Translocated bacteria activate innate immune cells and initiate local and systemic inflammation. Mechanisms of gut-associated toxicity and tumour clearance vary based on treatment type, and the microbial species that have been demonstrated to affect these mechanisms are listed at the top of the figure. Gut commensals, through myeloid differentiation primary response 88 (MYD88)- associated receptors, prime myeloid cells for the generation of reactive oxygen species (ROS), which, in the presence of Pt–DNA adducts formed in response to cisplatin or oxaliplatin, cause DNA damage62, 74. TBI used to condition patients before they receive adoptive T cell therapy induces mucosal damage and translocation of commensals, which through Toll-like receptor 4 (TLR4) signalling activate dendritic cells to sustain proliferation and cytotoxic functions of the transferred T cells153. CTX induces immunological cell death of tumour cells, which elicits the generation of antitumour pathogenic T helper 17 (pTH17) cells, TH1 cells and cytotoxic T lymphocytes (CTLs); CTX also induces damage to the mucosa and translocation of commensal bacteria that activate tumour antigen-presenting dendritic cells, enhancing the antitumour immune response61, 82. During CpG-oligodeoxynucleotide (ODN)–anti-interleukin-10 receptor (IL-10R) therapy, the gut microbiota, through TLR4 signalling, primes tumour-infiltrating myeloid cells to respond to the TLR9 agonist CpG-ODN, producing tumour necrosis factor (TNF) and other inflammatory cytokines that induce haemorrhagic necrosis of the tumour and an antitumour immune response62. Anti-CTLA4 immunotherapy promotes both antitumour and anti-commensal immunity; the anti-commensal immunity against specific genera, such as Burkholderiales and Bacteroidales (Bacteroides thetaiotaomicron and Bacteroides fragilis), results in mucosal damage and bacterial translocation but also serves as an adjuvant for the antitumour response33. The efficacy of anti- programmed cell death protein 1 ligand 1 (PDL1) therapy in generating antitumour immunity by preventing programmed cell death protein 1 (PD1) interaction with PDL1 is enhanced by the presence in the gut microbiota of Bifidobacterium spp. (Bifidobacterium breve, Bifidobacterium longum and Bifidobacteri-um adolescentis)152. A. shahii, Alistipes shahii; B. intestinihominis, Barnesiella intestinihominis; E. hirae, Enterococcus hirae; L. acidophilus, Lactobacillus acidophilus; L. johnsonii, Lactobacillus johnsonii.

  4. Microbiota-triggered innate immune receptors.
    Figure 4: Microbiota-triggered innate immune receptors.

    Microbial products (microorganism-associated molecular patterns; MAMPs) and endogenous ligands, often released following tissue damage (damage-associated molecular patterns; DAMPs) interact with membrane-bound and cytoplasmic innate immune receptors regulating nutrition, metabolism, tissue homeostasis, inflammation, innate and adaptive immunity and, to a lesser extent, morphogenesis213, 214, 215, 216, 217. The gut microbiota promotes platinum cancer therapy by signalling through myeloid differentiation primary response 88 (MYD88), an adaptor for both the Toll-like receptor (TLR) and the interleukin-1 receptor (IL-1R) families61, 62. ? denotes that the identity of the receptors are yet to be determined. Activation of TLR4 by MAMPs primes tumour myeloid cells to respond to the TLR9 agonist CpG-oligodeoxynucleotide (ODN), induces mucosal bacterial translocation following total body irradiation (TBI), which favours optimal anticancer activity of adoptive T cell transfer and mediates mucosal toxicity by methotrexate62, 86, 87. In response to immunogenic cell death mediated by oxaliplatin or cyclophosphamide (CTX), activation of TLR4 by DAMPs in combination with NOD-like receptor, pyrin domain-containing 3 (NLRP3) inflammasome activation induces antitumour T cell activation77. Activation of TLR2 by MAMPs protects against mucosal damage induced by chemotherapy or radiation86, 87, 88, 130, 131, 132. Radiation activates TLR3 and the inflammasome absent in melanoma 2 (AIM2) by inducing leakage of cellular RNA and double-strand DNA breaks, respectively, resulting in massive cell death and tissue damage127, 128, 129. The cytoplasmic nucleotide-binding oligomerization domain-containing 2 (NOD2) receptor recognizing bacterial muramyl dipeptides participates in the regulation of intestinal mucosa homeostasis and protects against chemotherapy-induced mucosal damage and bacterial translocation82, 92. The N-formyl peptide receptors (FPRs) recognize bacterial peptides as well as endogenous ligands218. FPR2 expressed on apical and lateral membranes of the colonic crypt has a crucial role in regulating intestinal homeostasis and inflammation219. The ability of anthracycline to elicit antitumour T cell immunity requires the interaction of FPR1 on dendritic cells with the endogenous ligand annexin-A1, which promotes stable contacts between dying cancer cells and dendritic cells79. A. shahii, Alistipes shahii; COX2, cyclooxygenase 2; HMGB1, high mobility group protein B1; L. acidophilus, Lactobacillus acidophilus; L. reuteri, Lactobacillus reuteri; L. rhamnosus, Lactobacillus rhamnosus; LPS, lipopolysaccharide; MDR1, multi-drug resistance protein 1; NOX, NADPH oxidase; NRF2, nuclear factor erythroid 2-related factor 2; ROS, reactive oxygen species; TNF, tumour necrosis factor.

Change history

Corrected online 04 April 2017
In this article the sentence 'however, in one study, overgrowth of Parabacteroides distasonis in mice treated with broad-spectrum antibiotics was observed to abrogate its antitumour effect' was incorrectly referenced. The correct reference for this sentence is 61.

References

  1. Costello, E. K., Stagaman, K., Dethlefsen, L., Bohannan, B. J. & Relman, D. A. The application of ecological theory toward an understanding of the human microbiome. Science 336, 12551262 (2012).
  2. Bosch, T. C. & McFall-Ngai, M. J. Metaorganisms as the new frontier. Zoology (Jena) 114, 185190 (2011).
  3. Dzutsev, A., Goldszmid, R. S., Viaud, S., Zitvogel, L. & Trinchieri, G. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur. J. Immunol. 45, 1731 (2015).
  4. Smith, K., McCoy, K. D. & Macpherson, A. J. Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. Semin. Immunol. 19, 5969 (2007).
  5. Gustafsson, B. E., Daft, F. S., McDaniel, E. G., Smith, J. C. & Fitzgerald, R. J. Effects of vitamin K-active compounds and intestinal microorganisms in vitamin K-deficient germfree rats. J. Nutr. 78, 461468 (1962).
  6. Gordon, H. A., Bruckner-Kardoss, E. & Wostmann, B. S. Aging in germ-free mice: life tables and lesions observed at natural death. J. Gerontol. 21, 380387 (1966).
  7. De Santis, S., Cavalcanti, E., Mastronardi, M., Jirillo, E. & Chieppa, M. Nutritional keys for intestinal barrier modulation. Front. Immunol. 6, 612 (2015).
  8. Vaishnava, S., Behrendt, C. L., Ismail, A. S., Eckmann, L. & Hooper, L. V. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host–microbial interface. Proc. Natl Acad. Sci. USA 105, 20858 (2008).
    This paper identified the role of microbiota signalling in maintaining the host–commensal homeostasis through MYD88-coupled receptors in epithelial cells.
  9. Peterson, L. W. & Artis, D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 14, 141153 (2014).
  10. Belkaid, Y. & Naik, S. Compartmentalized and systemic control of tissue immunity by commensals. Nat. Immunol. 14, 646653 (2013).
    This review discusses the role of the microbiota at different epithelial barriers in regulating immunity both locally and systemically.
  11. Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121141 (2014).
  12. Sender, R., Fuchs, S. & Milo, R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 14, e1002533 (2016).
  13. Chow, J., Tang, H. & Mazmanian, S. K. Pathobionts of the gastrointestinal microbiota and inflammatory disease. Curr. Opin. Immunol. 23, 473480 (2011).
  14. Erny, D. et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat. Neurosci. 18, 965977 (2015).
  15. Khosravi, A. et al. Gut microbiota promote hematopoiesis to control bacterial infection. Cell Host Microbe 15, 374381 (2014).
  16. Trompette, A. et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 20, 159166 (2014).
  17. Chung, W. S. F. et al. Modulation of the human gut microbiota by dietary fibres occurs at the species level. BMC Biol. 14, 3 (2016).
  18. Dinan, T. G. & Cryan, J. F. Regulation of the stress response by the gut microbiota: implications for psychoneuroendocrinology. Psychoneuroendocrinology 37, 13691378 (2012).
  19. Sommer, F. & Bäckhed, F. The gut microbiota engages different signaling pathways to induce Duox2 expression in the ileum and colon epithelium. Mucosal Immunol. 8, 372379 (2015).
  20. Wells, J. M., Rossi, O., Meijerink, M. & van Baarlen, P. Epithelial crosstalk at the microbiota–mucosal interface. Proc. Natl Acad. Sci. USA 108 (Suppl. 1), 46074614 (2011).
  21. Tulstrup, M. V.-L. et al. Antibiotic treatment affects intestinal permeability and gut microbial composition in Wistar rats dependent on antibiotic class. PLoS ONE 10, e0144854 (2015).
  22. Backhed, F. et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 17, 690703 (2015).
  23. Dominguez-Bello, M. G. et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl Acad. Sci. USA 107, 1197111975 (2010).
    References 22 and 23 describe the establishment of the human microbiota during early life.
  24. Faith, J. J. et al. The long-term stability of the human gut microbiota. Science 341, 1237439 (2013).
  25. Oh, J., Byrd, A. L., Park, M., Kong, H. H. & Segre, J. A. Temporal stability of the human skin microbiome. Cell 165, 854866 (2016).
  26. Goodrich, J. K. et al. Human genetics shape the gut microbiome. Cell 159, 789799 (2014).
  27. Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480484 (2009).
  28. David, L. A. et al. Host lifestyle affects human microbiota on daily timescales. Genome Biol. 15, R89 (2014).
  29. David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559563 (2014).
  30. Garrett, W. S. et al. Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell 16, 208219 (2009).
  31. Couturier-Maillard, A. et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J. Clin. Invest. 123, 700711 (2013).
  32. Hu, B. et al. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. Proc. Natl Acad. Sci. USA 110, 98629867 (2013).
    References 31 and 32 demonstrated that the carcinogenic phenotypes associated with dysbiosis of the microbiota in genetically mutated mice can be transmitted to wild-type mice by microbiota transfer.
  33. Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 10791084 (2015).
    This paper presented the first demonstration of the role of the microbiota in modulating responsiveness to anti-CTLA4 therapy.
  34. DeVita, V. T. Jr & Chu, E. A history of cancer chemotherapy. Cancer Res. 68, 86438653 (2008).
  35. Sancho-Martinez, S. M., Prieto-Garcia, L., Prieto, M., Lopez-Novoa, J. M. & Lopez-Hernandez, F. J. Subcellular targets of cisplatin cytotoxicity: an integrated view. Pharmacol. Ther. 136, 3555 (2012).
  36. Mitchell, E. P. Gastrointestinal toxicity of chemotherapeutic agents. Semin. Oncol. 33, 106120 (2006).
  37. Spanogiannopoulos, P., Bess, E. N., Carmody, R. N. & Turnbaugh, P. J. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat. Rev. Microbiol. 14, 273287 (2016).
  38. Li, H. & Jia, W. Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. Clin. Pharmacol. Ther. 94, 574581 (2013).
  39. Feng, R. et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci. Rep. 5, 12155 (2015).
  40. Maurice, C. F., Haiser, H. J. & Turnbaugh, P. J. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152, 3950 (2013).
  41. Montassier, E. et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment. Pharmacol. Ther. 42, 515528 (2015).
  42. Wilson, I. D. & Nicholson, J. K. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res. 179, 204222 (2017).
  43. Haiser, H. J. & Turnbaugh, P. J. Developing a metagenomic view of xenobiotic metabolism. Pharmacol. Res. 69, 2131 (2013).
  44. Carmody, R. N. & Turnbaugh, P. J. Host–microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J. Clin. Invest. 124, 41734181 (2014).
  45. Bjorkholm, B. et al. Intestinal microbiota regulate xenobiotic metabolism in the liver. PLoS ONE 4, e6958 (2009).
  46. Selwyn, F. P., Cheng, S. L., Klaassen, C. D. & Cui, J. Y. Regulation of hepatic drug-metabolizing enzymes in germ-free mice by conventionalization and probiotics. Drug Metab. Dispos. 44, 262274 (2016).
  47. Selwyn, F. P., Cui, J. Y. & Klaassen, C. D. RNA-Seq quantification of hepatic drug processing genes in germ-free mice. Drug Metab. Dispos. 43, 15721580 (2015).
  48. Selwyn, F. P. et al. Developmental regulation of drug-processing genes in livers of germ-free mice. Toxicol. Sci. 147, 84103 (2015).
  49. Kang, M. J. et al. The effect of gut microbiota on drug metabolism. Expert Opin. Drug Metab. Toxicol. 9, 12951308 (2013).
  50. Yip, L. Y. & Chan, E. C. Investigation of host-gut microbiota modulation of therapeutic outcome. Drug Metab. Dispos. 43, 16191631 (2015).
  51. Fujita, K. & Sparreboom, A. Pharmacogenetics of irinotecan disposition and toxicity: a review. Curr. Clin. Pharmacol. 5, 209217 (2010).
  52. Stringer, A. M. et al. Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol. Ther. 7, 19191925 (2008).
  53. Lin, X. B. et al. Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats. PLoS ONE 7, e39764 (2012).
  54. Dabek, M., McCrae, S. I., Stevens, V. J., Duncan, S. H. & Louis, P. Distribution of beta-glucosidase and beta-glucuronidase activity and of beta-glucuronidase gene gus in human colonic bacteria. FEMS Microbiol. Ecol. 66, 487495 (2008).
  55. McIntosh, F. M. et al. Phylogenetic distribution of genes encoding beta-glucuronidase activity in human colonic bacteria and the impact of diet on faecal glycosidase activities. Environ. Microbiol. 14, 18761887 (2012).
  56. Takasuna, K. et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 56, 37523757 (1996).
  57. Wallace, B. D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831835 (2010).
  58. Mego, M. et al. Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complement. Ther. Med. 23, 356362 (2015).
  59. Wallace, B. D. et al. Structure and inhibition of microbiome beta-glucuronidases essential to the alleviation of cancer drug toxicity. Chem. Biol. 22, 12381249 (2015).
  60. Lehouritis, P. et al. Local bacteria affect the efficacy of chemotherapeutic drugs. Sci. Rep. 5, 14554 (2015).
  61. Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971976 (2013).
    This paper describes the role of the microbiota in modulating the anticancer effect of CTX.
  62. Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967970 (2013).
    This paper describes the role of the microbiota in modulating the efficacy of cancer therapy with CpG-ODNs and platinum drugs.
  63. Galluzzi, L. et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 5, e1257 (2014).
  64. Roy, S., Ryals, M. M., Van den Bruele, A. B., Fitzgerald, T. S. & Cunningham, L. L. Sound preconditioning therapy inhibits ototoxic hearing loss in mice. J. Clin. Invest. 123, 49454949 (2013).
  65. Abuzeid, W. M. et al. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J. Clin. Invest. 119, 19741985 (2009).
  66. Pabla, N. & Dong, Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 73, 9941007 (2008).
  67. Wagner, J. M. & Karnitz, L. M. Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival. Mol. Pharmacol. 76, 208214 (2009).
  68. Zhu, S., Pabla, N., Tang, C., He, L. & Dong, Z. DNA damage response in cisplatin-induced nephrotoxicity. Arch. Toxicol. 89, 21972205 (2015).
  69. Park, S. B. et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J. Clin. 63, 419437 (2013).
  70. Hooper, L. V. & Macpherson, A. J. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat. Rev. Immunol. 10, 159169 (2010).
  71. Sonis, S. T. The pathobiology of mucositis. Nat. Rev. Cancer 4, 277284 (2004).
  72. Kim, S., Lee, T. J., Park, J. W. & Kwon, T. K. Overexpression of cFLIPs inhibits oxaliplatin-mediated apoptosis through enhanced XIAP stability and Akt activation in human renal cancer cells. J. Cell. Biochem. 105, 971979 (2008).
  73. Laurent, A. et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 65, 948956 (2005).
  74. Gui, Q. F., Lu, H. F., Zhang, C. X., Xu, Z. R. & Yang, Y. H. Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model. Genet. Mol. Res. 14, 56425651 (2015).
  75. Tesniere, A. et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482491 (2010).
  76. Michaud, M. et al. Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. Oncoimmunology 1, 393395 (2012).
  77. Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15, 11701178 (2009).
  78. Pateras, I. S. et al. The DNA damage response and immune signaling alliance: is it good or bad? Nature decides when and where. Pharmacol. Ther. 154, 3656 (2015).
  79. Vacchelli, E. et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science 350, 972978 (2015).
  80. Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 5172 (2013).
    This paper reviewed the mechanisms underlying the phenomenon of immunogenic cell death in cancer therapy.
  81. Zwielehner, J. et al. Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting. PLoS ONE 6, e28654 (2011).
  82. Daillere, R. et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity 45, 931943 (2016).
    This paper characterized the role of different bacterial species in regulating antitumour T cell responses induced by CTX.
  83. Ghoreschi, K. et al. Generation of pathogenic TH17 cells in the absence of TGF-beta signalling. Nature 467, 967971 (2010).
  84. Chitapanarux, I. et al. Randomized controlled trial of live Lactobacillus acidophilus plus Bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat. Oncol. 5, 31 (2010).
  85. Wang, Y. et al. Pharmacological inhibition of NADPH oxidase protects against cisplatin induced nephrotoxicity in mice by two step mechanism. Food Chem. Toxicol. 83, 251260 (2015).
  86. Cario, E. Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity. Curr. Opin. Support. Palliat. Care 10, 157164 (2016).
  87. Frank, M. et al. TLR signaling modulates side effects of anticancer therapy in the small intestine. J. Immunol. 194, 19831995 (2015).
  88. Mercado-Lubo, R. & McCormick, B. A. The interaction of gut microbes with host ABC transporters. Gut Microbes 1, 301306 (2010).
  89. Napenas, J. J. et al. Molecular methodology to assess the impact of cancer chemotherapy on the oral bacterial flora: a pilot study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 109, 554560 (2010).
  90. Niu, Q. Y., Li, Z. Y., Du, G. H. & Qin, X. M. 1H NMR based metabolomic profiling revealed doxorubicin-induced systematic alterations in a rat model. J. Pharm. Biomed. Anal. 118, 338348 (2016).
  91. Rigby, R. J. et al. Intestinal bacteria are necessary for doxorubicin-induced intestinal damage but not for doxorubicin-induced apoptosis. Gut Microbes 7, 414423 (2016).
  92. Nigro, G., Rossi, R., Commere, P. H., Jay, P. & Sansonetti, P. J. The cytosolic bacterial peptidoglycan sensor Nod2 affords stem cell protection and links microbes to gut epithelial regeneration. Cell Host Microbe 15, 792798 (2014).
  93. Jiang, C. et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun. 6, 10166 (2015).
  94. Parseus, A. et al. Microbiota-induced obesity requires farnesoid X receptor. Gut 66, 429437 (2016).
  95. Das, S. K. et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 333, 233238 (2011).
  96. Ruud, J. et al. Inflammation- and tumor-induced anorexia and weight loss require MyD88 in hematopoietic/myeloid cells but not in brain endothelial or neural cells. FASEB J. 27, 19731980 (2013).
  97. Suárez-Zamorano, N. et al. Microbiota depletion promotes browning of white adipose tissue and reduces obesity. Nat. Med. 21, 14971501 (2015).
  98. de Matos-Neto, E. M. et al. Systemic inflammation in cachexia — is tumor cytokine expression profile the culprit? Front. Immunol. 6, 629 (2015).
  99. Antoun, S., Baracos, V. E., Birdsell, L., Escudier, B. & Sawyer, M. B. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann. Oncol. 21, 15941598 (2010).
  100. Toledo, M. et al. A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy. J. Cachexia Sarcopenia Muscle 7, 4859 (2016).
  101. Conte, E. et al. Cisplatin-induced cachexia in rats causes alterations in skeletal muscle calcium homeostasis. Biophys. J. 108 (Suppl. 1), 108a (2015).
  102. Garcia, J. M., Cata, J. P., Dougherty, P. M. & Smith, R. G. Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. Endocrinology 149, 455460 (2008).
  103. Bruggeman, A. R. et al. Cancer cachexia: beyond weight loss. J. Oncol. Pract. 12, 11631171 (2016).
  104. Cvan Trobec, K. et al. Influence of cancer cachexia on drug liver metabolism and renal elimination in rats. J. Cachexia Sarcopenia Muscle 6, 4552 (2015).
  105. Bindels, L. B. & Delzenne, N. M. Muscle wasting: the gut microbiota as a new therapeutic target? Int. J. Biochem. Cell Biol. 45, 21862190 (2013).
  106. Klein, G. L., Petschow, B. W., Shaw, A. L. & Weaver, E. Gut barrier dysfunction and microbial translocation in cancer cachexia: a new therapeutic target. Curr. Opin. Support. Palliat. Care 7, 361367 (2013).
  107. Yeh, K. Y. et al. Omega-3 fatty acid-, micronutrient-, and probiotic-enriched nutrition helps body weight stabilization in head and neck cancer cachexia. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 116, 4148 (2013).
  108. Varian, B. J. et al. Beneficial bacteria inhibit cachexia. Oncotarget 7, 1180311816 (2016).
  109. Schieber, A. M. P. et al. Disease tolerance mediated by microbiome E. coli involves inflammasome and IGF-1 signaling. Science 350, 558563 (2015).
  110. Mavragani, I. V. et al. Key mechanisms involved in ionizing radiation-induced systemic effects. A current review. Toxicol. Res. 5, 1233 (2016).
  111. Azzam, E. I. & Little, J. B. The radiation-induced bystander effect: evidence and significance. Hum. Exp. Toxicol. 23, 6165 (2004).
  112. Vacchelli, E. et al. Trial Watch: anticancer radioimmunotherapy. Oncoimmunology 2, e25595 (2013).
  113. Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 10501059 (2007).
  114. Nikitaki, Z. et al. Systemic mechanisms and effects of ionizing radiation: a new 'old' paradigm of how the bystanders and distant can become the players. Semin. Cancer Biol. 37–38, 7795 (2016).
  115. Ermolaeva, M. A. et al. DNA damage in germ cells induces an innate immune response that triggers systemic stress resistance. Nature 501, 416420 (2013).
  116. Al-Mayah, A. et al. The non-targeted effects of radiation are perpetuated by exosomes. Mutat. Res. 772, 3845 (2015).
  117. Demaria, S. & Formenti, S. C. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front. Oncol. 2, 153 (2012).
  118. Demaria, S. et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58, 862870 (2004).
  119. Zitvogel, L., Ayyoub, M., Routy, B. & Kroemer, G. Microbiome and anticancer immunosurveillance. Cell 165, 276287 (2016).
  120. Deng, L. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687695 (2014).
  121. Baird, J. R. et al. Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors. Cancer Res. 76, 5061 (2016).
  122. Barker, H. E., Paget, J. T. E., Khan, A. A. & Harrington, K. J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15, 409425 (2015).
  123. Touchefeu, Y. et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis — current evidence and potential clinical applications. Aliment. Pharmacol. Ther. 40, 409421 (2014).
  124. Vanhoecke, B. W. et al. Low-dose irradiation affects the functional behavior of oral microbiota in the context of mucositis. Exp. Biol. Med. (Maywood) 241, 6070 (2016).
  125. Broin, P. Ó. et al. Intestinal microbiota-derived metabolomic blood plasma markers for prior radiation injury. Int. J. Radiat. Oncol. Biol. Phys. 91, 360367 (2015).
  126. Wang, A. et al. Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study. PLoS ONE 10, e0126312 (2015).
  127. Takemura, N. et al. Blockade of TLR3 protects mice from lethal radiation-induced gastrointestinal syndrome. Nat. Commun. 5, 3492 (2014).
  128. Vacchelli, E. et al. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2, e25238 (2013).
  129. Hu, B. et al. The DNA-sensing AIM2 inflammasome controls radiation-induced cell death and tissue injury. Science 354, 765768 (2016).
  130. Ciorba, M. A. et al. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut 61, 829838 (2012).
  131. Jones, R. M. et al. Lactobacilli modulate epithelial cytoprotection through the Nrf2 pathway. Cell Rep. 12, 12171225 (2015).
  132. Jones, R. M. et al. Symbiotic lactobacilli stimulate gut epithelial proliferation via Nox-mediated generation of reactive oxygen species. EMBO J. 32, 30173028 (2013).
  133. Delia, P. et al. Use of probiotics for prevention of radiation-induced diarrhea. World J. Gastroenterol. 13, 912915 (2007).
  134. Sharma, A. et al. Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: a randomized double-blind placebo-controlled study. Eur. J. Cancer 48, 875881 (2012).
  135. Crawford, P. A. & Gordon, J. I. Microbial regulation of intestinal radiosensitivity. Proc. Natl Acad. Sci. USA 102, 1325413259 (2005).
    This paper describes the radioresistance of germ-free mice and characterized the underlying molecular mechanisms.
  136. Santulli, G. Angiopoietin-like proteins: a comprehensive look. Front. Endocrinol. 5, 4 (2014).
  137. Grootaert, C. et al. Bacterial monocultures, propionate, butyrate and H2O2 modulate the expression, secretion and structure of the fasting-induced adipose factor in gut epithelial cell lines. Environ. Microbiol. 13, 17781789 (2011).
  138. Jacouton, E. et al. Lactobacillus rhamnosus CNCMI-4317 modulates Fiaf/Angptl4 in intestinal epithelial cells and circulating level in mice. PLoS ONE 10, e0138880 (2015).
  139. Korecka, A. et al. ANGPTL4 expression induced by butyrate and rosiglitazone in human intestinal epithelial cells utilizes independent pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 304, G1025G1037 (2013).
  140. Duncan, A. M., Ronen, A. & Blakey, D. H. Diurnal variation in the response of gamma-ray-induced apoptosis in the mouse intestinal epithelium. Cancer Lett. 21, 163166 (1983).
  141. Ishihara, H. et al. Circadian transitions in radiation dose-dependent augmentation of mRNA levels for DNA damage-induced genes elicited by accurate real-time RT-PCR quantification. J. Radiat. Res. 51, 265275 (2010).
  142. Ruifrok, A. C., Weil, M. M., Thames, H. D. & Mason, K. A. Diurnal variations in the expression of radiation-induced apoptosis. Radiat. Res. 149, 360365 (1998).
  143. Leone, V. et al. Effects of diurnal variation of gut microbes and high-fat feeding on host circadian clock function and metabolism. Cell Host Microbe 17, 681689 (2015).
  144. Liang, X., Bushman, F. D. & FitzGerald, G. A. Rhythmicity of the intestinal microbiota is regulated by gender and the host circadian clock. Proc. Natl Acad. Sci. USA 112, 1047910484 (2015).
  145. Mukherji, A., Kobiita, A., Ye, T. & Chambon, P. Homeostasis in intestinal epithelium is orchestrated by the circadian clock and microbiota cues transduced by TLRs. Cell 153, 812827 (2013).
  146. Nguyen, K. D. et al. Circadian gene Bmal1 regulates diurnal oscillations of Ly6Chi inflammatory monocytes. Science 341, 14831488 (2013).
  147. Thaiss, C. A. et al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell 159, 514529 (2014).
  148. Maier, I., Berry, D. M. & Schiestl, R. H. Intestinal microbiota reduces genotoxic endpoints induced by high-energy protons. Radiat. Res. 181, 4553 (2014).
  149. Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714726 (2013).
  150. Couzin-Frankel, J. Breakthrough of the year 2013. Cancer immunotherapy. Science 342, 14321433 (2013).
  151. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480489 (2011).
  152. Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 10841089 (2015).
    This paper demonstrated that the presence of Bifidobacterium spp. in the gut microbiota promotes antitumour immunity in mice that is amplified by anti-PDL1 therapy.
  153. Paulos, C. M. et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 117, 21972204 (2007).
    This paper used a therapy model of adoptive T cell transfer preceded by TBI in mice, to demonstrate for the first time that the microbiota modulates anticancer therapy.
  154. Dudley, M. E. et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 52335239 (2008).
  155. Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G. & Colombo, M. P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65, 34373446 (2005).
  156. Vicari, A. P. et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196, 541549 (2002).
  157. Stewart, C. A. et al. Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. J. Clin. Invest. 123, 48594874 (2013).
  158. Netea, M. G. et al. Trained immunity: a program of innate immune memory in health and disease. Science 352, aaf1098 (2016).
  159. Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909915 (2004).
  160. Eggermont, A. M. Therapeutic vaccines in solid tumours: can they be harmful? Eur. J. Cancer 45, 20872090 (2009).
  161. Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P. & Wolchok, J. D. Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185202 (2014).
  162. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 5661 (2015).
  163. Teply, B. A. & Lipson, E. J. Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park) 28 (Suppl. 3), 3038 (2014).
  164. Dubin, K. et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016).
  165. Hand, T. W. et al. Acute gastrointestinal infection induces long-lived microbiota-specific T cell responses. Science 337, 15531556 (2012).
  166. Yang, X. et al. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell 25, 3748 (2014).
  167. Zitvogel, L., Pitt, J. M., Daillere, R., Smyth, M. J. & Kroemer, G. Mouse models in oncoimmunology. Nat. Rev. Cancer 16, 759773 (2016).
  168. Ivanov, I. I., Frutos Rde, L., Manel, N., Yoshinaga, K. & Rifkin, D. B. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4, 337 (2008).
  169. Nowarski, R. et al. Epithelial IL-18 equilibrium controls barrier function in colitis. Cell 163, 14441456 (2015).
  170. Elinav, E. et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145, 745757 (2011).
  171. Wheeler, M. L. et al. Immunological consequences of intestinal fungal dysbiosis. Cell Host Microbe 19, 865873 (2016).
  172. Howitt, M. R. et al. Tuft cells, taste-chemosensory cells, orchestrate parasite type 2 immunity in the gut. Science 351, 13291333 (2016).
  173. Kernbauer, E., Ding, Y. & Cadwell, K. An enteric virus can replace the beneficial function of commensal bacteria. Nature 516, 9498 (2014).
  174. Cadwell, K. The virome in host health and disease. Immunity 42, 805813 (2015).
  175. Ramanan, D. et al. Helminth infection promotes colonization resistance via type 2 immunity. Science 352, 608612 (2016).
  176. Young, G. R. et al. Resurrection of endogenous retroviruses in antibody-deficient mice. Nature 491, 774778 (2012).
  177. Turnbaugh, P. J. et al. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci. Transl Med. 1, 6ra14 (2009).
  178. Baxter, N. T., Zackular, J. P., Chen, G. Y. & Schloss, P. D. Structure of the gut microbiome following colonization with human feces determines colonic tumor burden. Microbiome 2, 20 (2014).
  179. Plantinga, T. S. et al. Differential Toll-like receptor recognition and induction of cytokine profile by Bifidobacterium breve and Lactobacillus strains of probiotics. Clin. Vaccine Immunol. 18, 621628 (2011).
  180. Kadowaki, N. et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194, 863869 (2001).
  181. Pamer, E. G. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science 352, 535538 (2016).
  182. Goldszmid, R. S. & Trinchieri, G. The price of immunity. Nat. Immunol. 13, 932938 (2012).
  183. Jobin, C. Colorectal cancer: CRC — all about microbial products and barrier function? Nat. Rev. Gastroenterol. Hepatol. 9, 694696 (2012).
  184. Rao, V. P. et al. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res. 66, 73957400 (2006).
  185. Salcedo, R. et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J. Exp. Med. 207, 16251636 (2010).
  186. Allen, I. C. et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 207, 10451056 (2010).
  187. Sears, C. L. & Garrett, W. S. Microbes, microbiota, and colon cancer. Cell Host Microbe 15, 317328 (2014).
  188. Kostic, A. D. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14, 207215 (2013).
  189. Rubinstein, M. R. et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 14, 195206 (2013).
  190. Gur, C. et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42, 344355 (2015).
  191. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. Lyon, 7–14 June 1994. IARC Monogr. Eval. Carcinog. Risks Hum. 61, 1241 (1994).
  192. Poutahidis, T. et al. Pathogenic intestinal bacteria enhance prostate cancer development via systemic activation of immune cells in mice. PLoS ONE 8, e73933 (2013).
  193. Fox, J. G. et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 59, 8897 (2010).
  194. Yamamoto, M. L. et al. Intestinal bacteria modify lymphoma incidence and latency by affecting systemic inflammatory state, oxidative stress, and leukocyte genotoxicity. Cancer Res. 73, 42224232 (2013).
  195. Farrell, J. J. et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 61, 582588 (2012).
  196. Fan, X. et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut http://dx.doi.org/10.1136/gutjnl-2016-312580 (2016).
  197. Westbrook, A. M. et al. The role of tumour necrosis factor-alpha and tumour necrosis factor receptor signalling in inflammation-associated systemic genotoxicity. Mutagenesis 27, 7786 (2012).
  198. Gyurkocza, B., Rezvani, A. & Storb, R. F. Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev. Hematol. 3, 285299 (2010).
  199. Taur, Y., Jenq, R. R., Ubeda, C., van den Brink, M. & Pamer, E. G. Role of intestinal microbiota in transplantation outcomes. Best Pract. Res. Clin. Haematol. 28, 155161 (2015).
  200. Taur, Y. et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 124, 11741182 (2014).
  201. Jenq, R. R. et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J. Exp. Med. 209, 903911 (2012).
  202. Holler, E. et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol. Blood Marrow Transplant. 20, 640645 (2014).
  203. Taur, Y. et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin. Infect. Dis. 55, 905914 (2012).
  204. Jenq, R. R. et al. Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol. Blood Marrow Transplant. 21, 13731383 (2015).
  205. Ho, J. T. K., Chan, G. C. F. & Li, J. C. B. Systemic effects of gut microbiota and its relationship with disease and modulation. BMC Immunol. 16, 21 (2015).
  206. Boleij, A. et al. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin. Infect. Dis. 60, 208215 (2015).
  207. Koshiol, J. et al. Salmonella enterica serovar Typhi and gallbladder cancer: a case-control study and meta-analysis. Cancer Med. 5, 33103235 (2016).
  208. Lecuit, M. et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N. Engl. J. Med. 350, 239248 (2004).
  209. Senff, N. J. et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112, 16001609 (2008).
  210. Ferreri, A. J. et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J. Clin. Oncol. 30, 29882994 (2012).
  211. Lakritz, J. R. et al. Gut bacteria require neutrophils to promote mammary tumorigenesis. Oncotarget 6, 93879396 (2015).
  212. Rutkowski, M. R. et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 27, 2740 (2015).
  213. Chu, H. & Mazmanian, S. K. Innate immune recognition of the microbiota promotes host–microbial symbiosis. Nat. Immunol. 14, 668675 (2013).
  214. McFall-Ngai, M. et al. Animals in a bacterial world, a new imperative for the life sciences. Proc. Natl Acad. Sci. USA 110, 32293236 (2013).
  215. Kremer, N. et al. Initial symbiont contact orchestrates host-organ-wide transcriptional changes that prime tissue colonization. Cell Host Microbe 14, 183194 (2013).
  216. Hansen, C. H. et al. Patterns of early gut colonization shape future immune responses of the host. PLoS ONE 7, e34043 (2012).
  217. Stappenbeck, T. S., Hooper, L. V. & Gordon, J. I. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc. Natl Acad. Sci. USA 99, 1545115455 (2002).
  218. Le, Y. et al. Biologically active peptides interacting with the G protein-coupled formylpeptide receptor. Protein Pept. Lett. 14, 846853 (2007).
  219. Chen, K. et al. Formylpeptide receptor-2 contributes to colonic epithelial homeostasis, inflammation, and tumorigenesis. J. Clin. Invest. 123, 16941704 (2013).

Download references

Author information

Affiliations

  1. Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

    • Soumen Roy &
    • Giorgio Trinchieri

Competing interests statement

The authors declare no competing interests.

Corresponding author

Correspondence to:

Author details

  • Soumen Roy

    Soumen Roy is currently working in the field of gut microbiota, cancer and experimental immunology in the laboratory of G. Trinchieri, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA. He is interested in the role of the gut microbiota in modulating anticancer therapy-induced systemic toxicity. During his postdoctoral training in the laboratory of Lisa Cunningham, National Institute on Deafness and other Communication Disorders (NIDCD), NIH, he worked on developing a sound preconditioning-based co-therapy to prevent hearing loss from anticancer drug-induced ototoxicity. He obtained his Doctoral degree in the field of hearing research and targeted nanomedicine in the laboratory of Anneliese Schrott Fisher, Innsbruck Medical University, Austria.

  • Giorgio Trinchieri

    Giorgio Trinchieri is a National Institutes of Health (NIH) Distinguished Investigator and Director of the Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH. He received his M.D. from the University of Torino, Italy in 1973. Before his position at NCI, he served in multiple capacities at the Basel Institute for Immunology, Switzerland, the Medical Genetics Institute at the Medical School of Torino, the Wistar Institute and Department of Medicine of the University of Pennsylvania, Philadelphia, USA, the Swiss Institute for Experimental Cancer Research in Epalinges, Switzerland, the Schering Plough Laboratory for Immunological Research in Dardilly, France, and the Laboratory for Parasitic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, USA. For many years he has been interested in the interplay between inflammation/innate resistance and adaptive immunity, and in the role of pro-inflammatory cytokines and interferons in the regulation of haematopoiesis, innate resistance and immunity against infections and tumours. His laboratory's main focus is the role of inflammation, innate resistance, immunity and commensal microbiota in carcinogenesis, cancer progression and prevention or therapy of cancer.

Additional data